AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7839499 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting values of Pi/PCr
Number of subjects: 19
Study 7839499 — intervention group
Group type: COMPARATOR
Intervention: Pi/PCr and pH changes during work and recovery
Number of subjects: 19
Study 3066139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 2 mg/h
Number of subjects: 0
Study 3066139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 3 mg/h
Number of subjects: 0
Study 30594226 — intervention group
Group type: EXPERIMENTAL
Intervention: CaP-hybridized tendon graft method
Number of subjects: 90
Study 30594226 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 90
Study 30594226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 25611962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (1 mg/kg daily)
Number of subjects: 25
Study 25611962 — intervention group
Group type: COMPARATOR
Intervention: Transition from sildenafil to tadalafil
Number of subjects: 25
Study 25611962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil administration
Number of subjects: 25
Study 25649903 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy with fast-track treatment (LAFT)
Number of subjects: 92
Study 25649903 — intervention group
Group type: COMPARATOR
Intervention: Open surgery with fast-track treatment (OSFT)
Number of subjects: 92
Study 25649903 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy with conventional treatment (LAC)
Number of subjects: 92
Study 25649903 — intervention group
Group type: COMPARATOR
Intervention: Open surgery with conventional treatment (OSC)
Number of subjects: 92
Study 22938776 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm training using an adjustable pressure device (Threshold; Philips Respironics Inc)
Number of subjects: 69
Study 22938776 — intervention group
Group type: COMPARATOR
Intervention: No training (sham device)
Number of subjects: 69
Study 20854334 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT (computerized cognitive behavioral therapy)
Number of subjects: 52
Study 20854334 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 52
Study 18491421 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T+3TC
Number of subjects: 308
Study 18491421 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV+3TC
Number of subjects: 308
Study 18491421 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC+3TC
Number of subjects: 308
Study 18491421 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T+3TC and ZDV+3TC
Number of subjects: 308
Study 17699343 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 fatty acids)
Number of subjects: 0
Study 12880608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (400 ml daily of a supplement enriched with protein, arginine, zinc and antioxidants)
Number of subjects: 103
Study 12880608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-caloric, water-based supplement)
Number of subjects: 103
Study 12880608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 103
Study 12880608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 11082935 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins administered to 50 women
Number of subjects: 105
Study 11082935 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to 55 women
Number of subjects: 105
Study 11082935 — intervention group
Group type: COMPARATOR
Intervention: Control group of 60 healthy pregnant women
Number of subjects: 105
Study 9361661 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Cognitive Assessment Battery (TCAB) administered before in-person assessment
Number of subjects: 80
Study 9361661 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Cognitive Assessment Battery (TCAB)
Number of subjects: 80
Study 9361661 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 80
Study 1489122 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg intranasally)
Number of subjects: 18
Study 1489122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasally)
Number of subjects: 18
Study 3986441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (B/ECT)
Number of subjects: 37
Study 3986441 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT (U/ECT)
Number of subjects: 37
Study 31193363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness based intervention (Learning 2 Breath Mindfulness Curriculum)
Number of subjects: 23
Study 31193363 — intervention group
Group type: COMPARATOR
Intervention: Attention intervention
Number of subjects: 23
Study 28939265 — intervention group
Group type: EXPERIMENTAL
Intervention: comfilcon A lenses
Number of subjects: 20
Study 28939265 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon A lenses
Number of subjects: 20
Study 26975720 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive provided to authors (intervention group)
Number of subjects: 0
Study 26975720 — intervention group
Group type: COMPARATOR
Intervention: No financial incentive provided to authors (control group)
Number of subjects: 0
Study 24221450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist feedback intervention
Number of subjects: 695
Study 24221450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist feedback)
Number of subjects: 695
Study 24221450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist feedback intervention (men)
Number of subjects: 695
Study 24221450 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 695
Study 24221450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist feedback intervention (patients ≥70 years)
Number of subjects: 695
Study 24221450 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients ≥70 years)
Number of subjects: 695
Study 24221450 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 695
Study 22552046 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 16
Study 20354453 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m on days 1 and 8 (G)
Number of subjects: 83
Study 20354453 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m on days 1 and 8 plus docetaxel 75 mg/m on day 1 (GD)
Number of subjects: 83
Study 20354453 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel (GD)
Number of subjects: 83
Study 18024211 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC regimen (fluorouracil, epirubicin, and cyclophosphamide for six cycles)
Number of subjects: 125
Study 18024211 — intervention group
Group type: EXPERIMENTAL
Intervention: TET regimen (docetaxel for three cycles followed by epirubicin plus docetaxel for three cycles)
Number of subjects: 125
Study 18024211 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (FEC and TET)
Number of subjects: 125
Study 12633794 — intervention group
Group type: EXPERIMENTAL
Intervention: PMLR with optimal medical therapy (n = 36)
Number of subjects: 73
Study 12633794 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone (n = 37)
Number of subjects: 73
Study 10852758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) plus albuterol
Number of subjects: 180
Study 10852758 — intervention group
Group type: COMPARATOR
Intervention: Albuterol plus placebo (control)
Number of subjects: 180
Study 9235646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyme arthritis (LA)
Number of subjects: 45
Study 9235646 — intervention group
Group type: COMPARATOR
Intervention: Reactive arthritis (RA)
Number of subjects: 45
Study 8261405 — intervention group
Group type: COMPARATOR
Intervention: Oral VP16 daily for up to 21 days (Arm A)
Number of subjects: 31
Study 8261405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral VP16 daily for up to 21 days plus concomitant GM-CSF at 5 micrograms/kg/day (Arm B)
Number of subjects: 31
Study 8261405 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral VP16 daily for up to 21 days plus pretreatment with GM-CSF (Arm C)
Number of subjects: 31
Study 3913184 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic coronary bypass surgery
Number of subjects: 0
Study 3913184 — intervention group
Group type: COMPARATOR
Intervention: Adequate medical treatment
Number of subjects: 0
Study 3913184 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 0
Study 30635781 — intervention group
Group type: EXPERIMENTAL
Intervention: HHT-containing regimens (arm B)
Number of subjects: 59
Study 30635781 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy regimen comprising mainly of anthracyclines and cytarabine (arm A)
Number of subjects: 59
Study 30635781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 59
Study 28535639 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 110
Study 28535639 — intervention group
Group type: COMPARATOR
Intervention: Microscopic surgery
Number of subjects: 110
Study 26423851 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advice from health professionals to avoid constrictive clothing around the trunk along with anaemia prevention leaflets and skin-care leaflets.
Number of subjects: 616
Study 26423851 — intervention group
Group type: COMPARATOR
Intervention: Anaemia prevention leaflets and skin-care leaflets.
Number of subjects: 616
Study 26423851 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advice from health professionals to avoid constrictive clothing around the trunk.
Number of subjects: 616
Study 24171329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal cleansing in the previous 30 days
Number of subjects: 293
Study 24171329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal cleansing in the three days before baseline
Number of subjects: 293
Study 24171329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal cleansing for hygiene unrelated to sex
Number of subjects: 293
Study 24171329 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of cleansing
Number of subjects: 293
Study 24171329 — intervention group
Group type: EXPERIMENTAL
Intervention: Products used for washing
Number of subjects: 293
Study 24171329 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with having more than one sex partner in the previous three months
Number of subjects: 293
Study 24171329 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with experiencing itching in the genital area at baseline
Number of subjects: 293
Study 21329971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero-cell-culture-derived influenza vaccine
Number of subjects: 7250
Study 21329971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7250
Study 19766350 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 40
Study 19766350 — intervention group
Group type: COMPARATOR
Intervention: UVA plus placebo
Number of subjects: 40
Study 17192500 — intervention group
Group type: COMPARATOR
Intervention: 15-mg pioglitazone/500-mg metformin fixed-dose combination tablets
Number of subjects: 124
Study 17192500 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg pioglitazone/500-mg metformin coadministration of commercial tablets
Number of subjects: 124
Study 17192500 — intervention group
Group type: COMPARATOR
Intervention: 15-mg pioglitazone/850-mg metformin fixed-dose combination tablets
Number of subjects: 124
Study 17192500 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg pioglitazone/850-mg metformin coadministration of commercial tablets
Number of subjects: 124
Study 15358467 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 75 mg in capsule form followed by misoprostol 600 microg
Number of subjects: 480
Study 15358467 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 150 mg in tablet form followed by misoprostol 600 microg
Number of subjects: 480
Study 11083885 — intervention group
Group type: EXPERIMENTAL
Intervention: SLTA patients
Number of subjects: 316
Study 11083885 — intervention group
Group type: COMPARATOR
Intervention: Acute asthma patients (controls)
Number of subjects: 316
Study 9044163 — intervention group
Group type: COMPARATOR
Intervention: etoposide phosphate
Number of subjects: 29
Study 1417013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg intravenous injection)
Number of subjects: 63
Study 1417013 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 63
Study 1417013 — intervention group
Group type: COMPARATOR
Intervention: Rescue medication (4 mg intravenous dose of ondansetron)
Number of subjects: 63
Study 1417013 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 63
Study 1417013 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin elevation
Number of subjects: 63
Study 2998181 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dietary fiber
Number of subjects: 52
Study 2998181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30406840 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab plus doxorubicin
Number of subjects: 133
Study 29763766 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy breakfast
Number of subjects: 36
Study 29763766 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy breakfast
Number of subjects: 36
Study 29763766 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 36
Study 29763766 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 36
Study 27758945 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric Acid (UA) 1000 mg
Number of subjects: 411
Study 27758945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 24732316 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS-variant
Number of subjects: 467
Study 24732316 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type alleles
Number of subjects: 467
Study 24732316 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 endometrial cancers
Number of subjects: 467
Study 24732316 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA expression
Number of subjects: 467
Study 22315480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 1324
Study 22315480 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1324
Study 22315480 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1324
Study 22315480 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1324
Study 20237484 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine eye drops (0.5%)
Number of subjects: 40
Study 20237484 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 20237484 — intervention group
Group type: EXPERIMENTAL
Intervention: Second ROP screening (regardless of type of drops used)
Number of subjects: 40
Study 18188581 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR) supplementation (approximately 10 g day(-1) over 3 months)
Number of subjects: 18
Study 18188581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) (dextrose)
Number of subjects: 18
Study 18188581 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR) supplementation
Number of subjects: 18
Study 18188581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 16822133 — intervention group
Group type: EXPERIMENTAL
Intervention: Binding of visual features (shape-color combinations)
Number of subjects: 0
Study 16822133 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning of feature-conjunction probabilities
Number of subjects: 0
Study 12719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 to 4 mg, n=28)
Number of subjects: 168
Study 12719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 to 160 mg, n=29)
Number of subjects: 168
Study 12719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 to 60 mg, n=28)
Number of subjects: 168
Study 12719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg, n=28)
Number of subjects: 168
Study 12719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg, n=29)
Number of subjects: 168
Study 12719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 to 10 mg, n=28)
Number of subjects: 168
Study 12719441 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 healthy subjects)
Number of subjects: 168
Study 12719441 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (25 microg/s)
Number of subjects: 168
Study 10818412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CA) COC (2 mg CA + 0.035 mg ethinylestradiol)
Number of subjects: 24
Study 10818412 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (D) COC (0.150 mg D + 0.030 mg ethinylestradiol)
Number of subjects: 24
Study 8804868 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg each morning and clarithromycin 500 mg three times daily for 2 weeks
Number of subjects: 44
Study 8804868 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg twice daily and clarithromycin 500 mg three times daily for 2 weeks
Number of subjects: 44
Study 1611221 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation of 800 mg daily (as calcium lactate gluconate)
Number of subjects: 50
Study 1611221 — intervention group
Group type: EXPERIMENTAL
Intervention: Load-bearing exercise four times a week plus a daily placebo tablet
Number of subjects: 50
Study 1611221 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation daily and load-bearing exercise four times a week
Number of subjects: 50
Study 1611221 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet daily
Number of subjects: 50
Study 30303614 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) diet during pregnancy
Number of subjects: 370
Study 30303614 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard dietary advice)
Number of subjects: 370
Study 27555316 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole for 5 days
Number of subjects: 238
Study 27555316 — intervention group
Group type: COMPARATOR
Intervention: Aspirin for 5 days
Number of subjects: 238
Study 26069138 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral and head elevated position (group HE)
Number of subjects: 44
Study 26069138 — intervention group
Group type: COMPARATOR
Intervention: Right lateral position (group L)
Number of subjects: 44
Study 23166195 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains (ITCs)
Number of subjects: 2037
Study 23166195 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2037
Study 21169609 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PF (popliteal + femoral)
Number of subjects: 50
Study 21169609 — intervention group
Group type: COMPARATOR
Intervention: Group P (popliteal)
Number of subjects: 50
Study 21353445 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone (IM)
Number of subjects: 230
Study 21353445 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone (SM)
Number of subjects: 230
Study 17486348 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose steroid treatment for optic nerve neuritis
Number of subjects: 0
Study 17486348 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment for traumatic optic neuropathy
Number of subjects: 0
Study 16294137 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily alendronate therapy
Number of subjects: 20
Study 16294137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12006325 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil CD64 expression in patients with active inflammatory disease
Number of subjects: 96
Study 12006325 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil CD64 expression in patients with systemic infection
Number of subjects: 96
Study 12006325 — intervention group
Group type: COMPARATOR
Intervention: Neutrophil CD64 expression in control patients (osteoarthritis and fibromyalgia)
Number of subjects: 96
Study 12006325 — intervention group
Group type: EXPERIMENTAL
Intervention: CD64 expression on neutrophils to diagnose systemic infection
Number of subjects: 96
Study 9710005 — intervention group
Group type: EXPERIMENTAL
Intervention: Campylobacter jejuni lipopolysaccharides (LPSs)
Number of subjects: 7
Study 9710005 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects or patients with uncomplicated Campylobacter diarrhea
Number of subjects: 7
Study 7824142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence processing measures (sentence‐picture matching, grammaticality judgments, sentence completion)
Number of subjects: 0
Study 2228714 — intervention group
Group type: EXPERIMENTAL
Intervention: PaperChase (self‐service computerized literature search)
Number of subjects: 57
Study 2228714 — intervention group
Group type: COMPARATOR
Intervention: Conventional resources (manually self‐performed searches and computerized MEDLINE searches by hospital librarians)
Number of subjects: 57
Study 2228714 — intervention group
Group type: EXPERIMENTAL
Intervention: PaperChase
Number of subjects: 57
Study 641312 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergobasine and ergotamine tartrate
Number of subjects: 30
Study 641312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 31318038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at a dose of 2 mcg/kg (max 100 mcg)
Number of subjects: 75
Study 31318038 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam at a dose of 0.5 mg/kg (max 15 mg)
Number of subjects: 75
Study 31318038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 75
Study 31318038 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam
Number of subjects: 75
Study 28715495 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based scenario training
Number of subjects: 119
Study 28715495 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture-word imagery training
Number of subjects: 119